BMO Capital keeps an Outperform rating Gilead (GILD) after the Wall Street Journal reported that Robert F. Kennedy Jr. plans ...

Amidst limited doses, priority will be given to those at substantial risk of HIV acquisition, such as adolescent girls and young women who are engaged in marital or concurrent sexual partnerships." ...

Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.